BI exec Belknap named chairman of wholesaler group’s research arm
ARLINGTON, Va. Boehringer Ingelheim Pharmaceuticals executive Robert Belknap has been named chairman of The Center for Healthcare Supply Chain Research, the research foundation of the Healthcare Distribution Management Association.
Belknap is executive director, trade sales & operations for the big pharmaceutical company. Prior to joining BI, he was senior director, global professional affairs for Wyeth Pharmaceutical, where he held a range of positions during his 19-year tenure.
Named vice chairman of the foundation’s board is Antonio “Tony” Pera, SVP supply chain management for AmerisourceBergen Drug Company. The board also named three new members, including John Harrington of sanofi-aventis U.S., Jeffrey Herzfeld of TEVA Pharmaceuticals USA and Hal Korman of Mylan Pharmaceuticals, Inc.
“On behalf of the Center for Healthcare Supply Chain Research, I would like to welcome Bob…and look forward to working with him,” said Karen Ribler, executive VP and COO of the Center. “His vision, leadership skills and forward-looking strategy will surely contribute value to the Center’s mission of providing research and education to enhance the safety and efficiency of the healthcare supply chain.”
Ribler also praised Belknap’s predecessor as chairman, McKesson Specialty president Robert Blake. “During his tenure, the Center made tremendous strides, including launching several strategic research initiatives and changing its name to better reflect our work.”
The Center for Healthcare Supply Chain Research, formerly the HDMA Research and Education Foundation, is a 501(c)(3) non-profit charitable organization that serves as the research arm of HDMA. Its mission, according to the wholesale drug industry trade group, is twofold: “To conduct research and disseminate information that will enhance the knowledgebase, efficiency and effectiveness of the total healthcare supply chain; and to provide thought leadership to further enhance the safety and security of the healthcare supply chain through future focused study and programming.”
Harris Poll: More consumers buying generics, drugs at Wal-Mart-like stores
ROCHESTER, N.Y. How and where people by prescription drugs and what drugs they buy have changed substantially over the past two years, according to the Harris Poll.
The poll, released Monday, found that between October 2006 and December 2008, the proportion of adults who would choose generic drugs over branded drugs increased from 68% to 81%, and the number who would choose branded drugs decreased from 32% to 19%.
Mass merchandisers have also gotten more customers at their pharmacies. Purchases of drugs at stores like Wal-Mart and Target increased from 13% to 17%, while purchases through mail-order and online pharmacies increased from 11% to 15%. Meanwhile, retail pharmacy chains have seen a decrease, from 39% to 33%, while purchases at independent pharmacies have dropped from 12% to 8%.
The poll was based on an online survey of 2,388 adults nationwide conducted between Dec. 9 and 15. Results were weighted for factors such as age, sex, household income, education, race and ethnicity.
Coster joins independent Rx team to spearhead government affairs, policy
ALEXANDRIA, Va. Retail pharmacy and policy veteran John Coster has joined the National Community Pharmacists Association as SVP government affairs, succeeding Charlie Sewell. His appointment to the independent pharmacy organization is effective immediately.
Coster, a licensed pharmacist and vocal advocate for the profession, is well known to pharmacy stakeholders and to policymaking staffs on Capitol Hill. He last served as VP federal affairs and public policy for Rite Aid Corp., and prior to that was the high-profile VP policy and programs for the National Association of Chain Drug Stores.
Coster has also worked for former Senator David Pryor, D-Ark., and on the staff of the U.S. Senate Special Committee on Aging and within the Congressional Office of Technology Assessment. He also served on the Task Force on Health Care Reform during the Clinton Administration.
NCPA EVP and CEO Bruce Roberts praised Coster as a well-respected expert in pharmacy and public policy. “As a pharmacist himself, with extensive legislative and policy experience, John will be an outstanding addition to the NCPA team. We are pleased that a pharmacist will be a strong voice for community pharmacy on Capitol Hill and in the regulatory agencies,” said Roberts.
Added NCPA president Holly Henry, “I look forward to having John Coster represent community pharmacy for NCPA in Washington, D.C. John’s expertise will give community pharmacy the competitive advantage it needs to be part of the overall health care dialogue.”
Coster, who earned a degree in pharmacy from St. John’s University in New York, and his Masters and Ph.D. in Policy Sciences with a concentration in health from the University of Maryland Graduate School, remains a licensed pharmacist in New York, Maryland and Virginia.